Brain cancer treatment receives Orphan Drug Designation
pharmafile | July 19, 2022 | News story | Manufacturing and Production |
The FDA has granted an Orphan Drug Designation for DSP-0390, an investigational emopamil-binding protein (EBP) inhibitor for the treatment of brain cancer, developed by Sumitomo Pharma Oncology, Inc.
DSP-0390 has shown cytotoxic activity against GBM, colorectal cancer, and triple-negative breast cancer in vitro. DSP-0390 is currently being evaluated in a Phase I, interventional clinical trial to evaluate the safety and efficacy of DSP-0390 in patients with recurrent high-grade glioma.
“This designation for DSP-0390 underscores the profound need for novel brain cancer treatment options,” said Patricia S Andrews, CEO and Global Head of Oncology, Sumitomo Pharma Oncology, Inc. “We are excited to contribute to advancing critical research in brain cancer.”
“DSP-0390 is an emopamil-binding protein (EBP) inhibitor that mediates de novo cholesterol synthesis for cell membrane structure and signaling, enabling aberrant growth of tumors,” detailed Jatin J Shah, MD, CMO Officer of Sumitomo Pharma Oncology, Inc. “Notably, in patients with glioblastoma multiforme (GBM), a form of high-grade glioma, increased de novo cholesterol synthesis is correlated with poor survival and preclinical evidence has shown that DSP-0390 has cytotoxic activity against GBM cell lines.”
The FDA’s Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the US. Brain cancer refers to brain tumours, made up of abnormal growth of cells in the brain, which are malignant. The exact cause of most brain cancer is still unknown.